Your browser doesn't support javascript.
loading
Cost-Utility Analysis of Screening for Diabetic Retinopathy in China.
Zhang, Yue; Bai, Weiling; Li, Ruyue; Du, Yifan; Sun, Runzhou; Li, Tao; Kang, Hong; Yang, Ziwei; Tang, Jianjun; Wang, Ningli; Liu, Hanruo.
Affiliation
  • Zhang Y; Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing, China.
  • Bai W; Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing, China.
  • Li R; Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing, China.
  • Du Y; Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing, China.
  • Sun R; Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing, China.
  • Li T; College of Computer Science, Nankai University, Tianjin, China.
  • Kang H; College of Computer Science, Nankai University, Tianjin, China.
  • Yang Z; School of Agricultural Economics and Rural Development, Renmin University of China, Beijing, China.
  • Tang J; School of Agricultural Economics and Rural Development, Renmin University of China, Beijing, China.
  • Wang N; Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing, China.
  • Liu H; National Institute of Health Data Science at Peking University, Beijing, China.
Health Data Sci ; 2022: 9832185, 2022.
Article de En | MEDLINE | ID: mdl-38487485
ABSTRACT
Background. Diabetic retinopathy (DR) has been primarily indicated to cause vision impairment and blindness, while no studies have focused on the cost-utility of telemedicine-based and community screening programs for DR in China, especially in rural and urban areas, respectively.Methods. We developed a Markov model to calculate the cost-utility of screening programs for DR in DM patients in rural and urban settings from the societal perspective. The incremental cost-utility ratio (ICUR) was calculated for the assessment.Results. In the rural setting, the community screening program obtained 1 QALY with a cost of $4179 (95% CI 3859 to 5343), and the telemedicine screening program had an ICUR of $2323 (95% CI 1023 to 3903) compared with no screening, both of which satisfied the criterion of a significantly cost-effective health intervention. Likewise, community screening programs in urban areas generated an ICUR of $3812 (95% CI 2906 to 4167) per QALY gained, with telemedicine screening at an ICUR of $2437 (95% CI 1242 to 3520) compared with no screening, and both were also cost-effective. By further comparison, compared to community screening programs, telemedicine screening yielded an ICUR of 1212 (95% CI 896 to 1590) per incremental QALY gained in rural setting and 1141 (95% CI 859 to 1403) in urban setting, which both meet the criterion for a significantly cost-effective health intervention.Conclusions. Both telemedicine and community screening for DR in rural and urban settings were cost-effective in China, and telemedicine screening programs were more cost-effective.

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Health Data Sci / Health data sci / Health data science Année: 2022 Type de document: Article Pays d'affiliation: Chine Pays de publication: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Health Data Sci / Health data sci / Health data science Année: 2022 Type de document: Article Pays d'affiliation: Chine Pays de publication: États-Unis d'Amérique